AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS
The collaboration agreement will see the development and commercialization of the target, TMEM175 involved in Parkinson’s disease and other neurodegenerative conditions.
Kojin launched with a $60 million Series A to focus on oncology and cell state biology led by Polaris Partners, Newpath Partners and Cathay Health.
AbbVie has been the target of multiple legal inquiries and challenges of its pricing and patent protections. Now, a U.S. senator is taking a gander at the company’s taxes.
Migraine headaches can be reduced in frequency and severity by atogepant, an oral therapy developed by AbbVie. So migraines will be gone sooner than we think.
Newly entrenched in a leadership role within one of the most complex therapeutic spaces, Tole discussed the complexities of being both a woman and a woman of color in the biotech industry.
AbbVie is aiming Skyrizi and Rinvoq at various indications to augment expected declines in the use of its $20-billion-generating-powerhouse Humira, which will lose patent protection in 2023.
House Oversight and Reform Committee slammed AbbVie for price increases on its drugs Humira Imbruvica. It said the company profited from patients and taxpayers.
AbbVie’s Allergan Aesthetics’ most well-known brands right now include BOTOX and CoolSculpting, among others. However, with the company’s latest acquisition, another one might slide its way to the top.
“The recent progress of cystic fibrosis drugs has been amazing and, in my case, miraculous,” said Kelly Peters, who lives with cystic fibrosis. “The new drugs are not a cure, but they feel pretty close.”
JOBS
IN THE PRESS